These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3116737)

  • 1. Augmentation of cell-mediated cytotoxicity against renal carcinoma cells by recombinant interleukin 2.
    Marumo K; Ueno M; Muraki J; Baba S; Tazaki H
    Urology; 1987 Oct; 30(4):327-32. PubMed ID: 3116737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative study of the activating effects of recombinant human interleukin 2 and interferon-gamma on cell-mediated cytotoxicity against renal cell carcinoma in vitro].
    Marumo K; Ueno M; Baba S; Muraki J; Deguchi N; Tazaki H
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1825-9. PubMed ID: 3109327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 2 induced cytotoxicity on renal cell carcinoma. 1. In vitro enhancement of natural killer cell activity.
    Ueno M
    Keio J Med; 1986 Jun; 35(2):80-9. PubMed ID: 3097369
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells.
    Ostensen ME; Thiele DL; Lipsky PE
    J Immunol; 1987 Jun; 138(12):4185-91. PubMed ID: 3108384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
    Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
    Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 2 induced cytotoxicity on renal cell carcinoma. 2. Synergistic effects of interleukin 2 and interferon gamma.
    Ueno M
    Keio J Med; 1986 Jun; 35(2):90-100. PubMed ID: 3097370
    [No Abstract]   [Full Text] [Related]  

  • 7. Natural killer (NK)-resistant human lung cancer cells are lysed by recombinant interleukin-2-activated NK cells.
    Robinson BW; Morstyn G
    Cell Immunol; 1987 May; 106(2):215-22. PubMed ID: 3494538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes.
    Schleypen JS; Von Geldern M; Weiss EH; Kotzias N; Rohrmann K; Schendel DJ; Falk CS; Pohla H
    Int J Cancer; 2003 Oct; 106(6):905-12. PubMed ID: 12918068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic effects of recombinant interferon-gamma in patients with renal cell carcinoma.
    Marumo K; Murai M; Deguchi N; Ikeuchi K; Tazaki H
    Keio J Med; 1990 Jun; 39(2):97-101. PubMed ID: 2120502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.
    Smyth MJ; Cretney E; Takeda K; Wiltrout RH; Sedger LM; Kayagaki N; Yagita H; Okumura K
    J Exp Med; 2001 Mar; 193(6):661-70. PubMed ID: 11257133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heterogeneity of a KU-2 cell line derived from human renal cell carcinoma--differential susceptibilities of its sublines to NK cell-mediated cytotoxicity].
    Hayakawa M; Osawa A; Nagakura K; Kikuchi H
    Hinyokika Kiyo; 1985 May; 31(5):763-8. PubMed ID: 4050622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo activation of LAK cells during systemic IL-2 therapy.
    Lang P; Vitté-Mony I; Farace F; Stancou R; Triebel F; Escudier B; Hercend T; Bertoglio J
    Eur Cytokine Netw; 1990; 1(3):185-8. PubMed ID: 2129800
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of stimulating interleukin -2/anti- interleukin -2 antibody complexes on renal cell carcinoma.
    Han KH; Kim KW; Yan JJ; Lee JG; Lee EM; Han M; Cho EJ; Kang SS; Lim HJ; Koo TY; Ahn C; Yang J
    BMC Urol; 2016 Jan; 16():2. PubMed ID: 26772545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
    Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
    Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat shock protein (HSP72) surface expression enhances the lysis of a human renal cell carcinoma by IL-2 stimulated NK cells.
    Roigas J; Wallen ES; Loening SA; Moseley PL
    Adv Exp Med Biol; 1998; 451():225-9. PubMed ID: 10026876
    [No Abstract]   [Full Text] [Related]  

  • 16. [A study of effective administration of recombinant interferon-gamma in renal cell carcinoma regarding immunological influence on peripheral blood lymphocytes].
    Kawata N; Ono M; Kodama M; Yamanaka Y; Hirakata H; Hirano D; Fuse T; Takimoto Y
    Hinyokika Kiyo; 1995 Jan; 41(1):21-6. PubMed ID: 7900565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K; Tilden AB; Balch CM
    J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
    Lanier LL; Benike CJ; Phillips JH; Engleman EG
    J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
    Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
    Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
    Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
    Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.